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OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) ago-
nists are used to treat type 2 diabetes, and transient GLP-1
administration improved cardiac function in humans after acute
myocardial infarction (MI) and percutaneous revascularization.
However, the consequences of GLP-1R activation before isch-
emic myocardial injury remain unclear.
RESEARCH DESIGN AND METHODS—We assessed the
pathophysiology and outcome of coronary artery occlusion in
normal and diabetic mice pretreated with the GLP-1R agonist
liraglutide.
RESULTS—Male C57BL/6 mice were treated twice daily for 7
days with liraglutide or saline followed by induction of MI.
Survival was signiﬁcantly higher in liraglutide-treated mice. Lira-
glutide reduced cardiac rupture (12 of 60 versus 46 of 60; P 
0.0001) and infarct size (21  2% versus 29  3%, P  0.02) and
improved cardiac output (12.4  0.6 versus 9.7  0.6 ml/min; P 
0.002). Liraglutide also modulated the expression and activity of
cardioprotective genes in the mouse heart, including Akt, GSK3,
PPAR-, Nrf-2, and HO-1. The effects of liraglutide on survival
were independent of weight loss. Moreover, liraglutide conferred
cardioprotection and survival advantages over metformin, de-
spite equivalent glycemic control, in diabetic mice with experi-
mental MI. The cardioprotective effects of liraglutide remained
detectable 4 days after cessation of therapy and may be partly
direct, because liraglutide increased cyclic AMP formation and
reduced the extent of caspase-3 activation in cardiomyocytes in
a GLP-1R–dependent manner in vitro.
CONCLUSIONS—These ﬁndings demonstrate that GLP-1R ac-
tivation engages prosurvival pathways in the normal and diabetic
mouse heart, leading to improved outcomes and enhanced
survival after MI in vivo. Diabetes 58:975–983, 2009
T
he protection against ischemic damage provided
by cycling periods of ischemia and reperfusion,
that is, ischemic preconditioning (IP), may last
for hours or even days (1). Although the molec-
ular basis of ischemic preconditioning is complex and
incompletely understood, there is active interest in the
development of therapeutic interventions that protect the
myocardium against ischemic injury.
Glucagon-like peptide-1 (GLP-1), a member of the pro-
glucagon-derived peptide family (2), exerts favorable ac-
tions on cardiovascular function in both preclinical and
clinical studies. A functional GLP-1 receptor (GLP-1R) is
expressed in the heart (3), and GLP-1R agonists directly
activate cardiomyocyte signaling pathways (4). Because
the GLP-1R is also expressed in the endocrine pancreas,
GLP-1 may regulate cardiac function indirectly through
metabolic control of glucose, insulin, glucagon, and free
fatty acids. Furthermore, GLP-1R agonists activate the
peripheral and central nervous system (CNS), including
regions of the CNS important for control of cardiovascular
function (5–7). The mechanisms through which GLP-1 can
modulate cardiac function are complex and incompletely
understood.
Transient GLP-1 administration improves outcomes in
experimental models of cardiac injury such as pacing-
induced heart failure (8) and experimental ischemia in-
duced by coronary artery ligation (9–13). A pilot study of
GLP-1 administration for 72 h in human subjects with left
ventricular (LV) dysfunction after myocardial injury and
angioplasty demonstrated reduced hospital stay and im-
proved global and regional LV wall motion scores, beneﬁts
that remained detectable even several weeks after hospital
discharge (14). Similarly, a 5-week course of GLP-1 infu-
sion improved parameters of LV function, functional sta-
tus, and quality of life in both diabetic and nondiabetic
subjects with congestive heart failure (15).
Although the glucoregulatory actions of the ﬁrst clini-
cally approved GLP-1R agonist, exenatide, have been
extensively studied in the clinic (2), there is limited
information available about the effects of exenatide on the
normal or ischemic heart (16). A second GLP-1R agonist,
liraglutide, is a human dipeptidyl peptidase-4 (DPP-4)-
resistant GLP-1 analog that exhibits a prolonged pharma-
cokinetic proﬁle, relative to native GLP-1, resulting from
noncovalent association with albumin (2,17,18), and has
completed phase 3 clinical trials in human subjects with
type 2 diabetes. Although liraglutide appears to be a promis-
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cardiovascular system have not been examined.
We have now assessed whether liraglutide exerts car-
dioprotective actions in a preclinical murine model of
experimental ischemia after coronary artery occlusion. We
show that treatment with liraglutide before induction of
ischemia leads to activation of prosurvival kinases and
cytoprotective genes in the heart and limits infarct size,
expansion, and cardiac rupture in the normal and diabetic
heart. Moreover, liraglutide increases cAMP and reduces
apoptosis in a GLP-1R–dependent manner in murine car-
diomyocytes cultured in vitro. These ﬁndings extend our
understanding of the cardioprotective actions of GLP-1R
agonists and provide testable hypotheses for examining
the cardiovascular effects of GLP-1R agonists in human
subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS
Animals. Protocols were approved by the Animal Care Committee of the
Toronto General Hospital in accordance with guidelines of the Canadian
Council for Animal Care. Male 10- to 12-week-old C57BL/6 mice were obtained
from Charles River (Montreal, PQ, Canada) and housed for at least 2 weeks
before experimentation.
Drug treatments. The volume of individual i.p. injections was 100 l. The
experimental protocols are summarized in supplemental Fig. 1 (available in an
online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db08-
1193). One group of animals (n  75) was injected with the GLP-1R agonist
liraglutide (Novo Nordisk, Novo Alle, Bagsvaerd, Denmark) at a previously
used dose of 200 g/kg i.p. twice daily (18) for 7 days before permanent
surgical ligation of the left anterior descending (LAD) artery as previously
detailed (20). A parallel group of control animals (n  75) was injected with
an equivalent volume of the vehicle, PBS. After this treatment period, some
animals (n  10 per group) were killed just before planned LAD ligation with
hearts dissected immediately, weighed, and frozen. A second group of mice
received PBS or liraglutide (n  10 each) for 7 days and were subjected to
sham surgery without LAD occlusion. Because a regimen of liraglutide 200
g/kg i.p twice daily (LIR 200) induced weight loss in mice, we also studied
the effects of LAD ligation in separate groups of mice after administration of
a lower dose of liraglutide (75 g/kg i.p. twice daily: LIR 75) that did not
produce signiﬁcant weight loss or pair-feeding to induce weight loss in control
animals comparable to that seen in mice treated with LIR 200. Separate groups
of PBS- and liraglutide-treated mice (n  13 per group) were killed on day 4
post–myocardial infarction (MI) for biochemical and histological analyses. LV
tissues from infarct and peri-infarct zones and remote (noninfarcted) area
were separated, snap-frozen, and stored at 80°C. The remaining mice were
monitored for 28 days post-MI for survival analysis and histomorphometry for
infarct size. In separate studies, mice were maintained on a high-fat diet (45%
Kcal from fat, D-12451; Research Diets) for 1 month, following which diabetes
was induced by treatment with streptozotocin (90 mg/kg i.p.). After stratiﬁ-
cation by degree of hyperglycemia at 3 weeks after streptozotocin injection,
mice were randomized to receive treatment for 7 days with placebo (PBS, 100
l i.p. twice daily), metformin in chow (6.76 g/kg of mouse diet), or liraglutide
75 g twice daily (LIR 75) before sham or LAD-ligation surgery (n  23/group:
5 sham, 18 LAD-ligation). Diabetic mice were maintained on the high-fat diet
until euthanasia on day 28 postsurgery. To investigate the role of the known
GLP-1R in the cardiac actions of liraglutide, male Glp1r-/- mice, 10 to 12 weeks
of age, in the C57BL/6 background and their littermate (Glp1r/) controls
(n  6/group), were injected with either PBS or 75 g liraglutide twice daily
for 1 week, then killed and their hearts used for Western blot assessment of
prosurvival kinases.
Necropsy. Cardiac examinations were performed on deceased mice post-MI.
The presence of a large amount of blood or clot around the heart and in the
thoracic cavity as well as a perforation of the infarct or peri-infarct area was
taken to indicate cardiac rupture.
Blood glucose. Before anesthesia, nonfasting blood glucose measurements
were obtained through a tail nick using a handheld glucometer and One-Touch
glucometer strips (LifeScan Canada, Burnaby, BC, Canada).
Cardiac hypertrophy. Heart-to-body weight ratios were calculated for each
animal at the time of terminal euthanasia.
Infarct size. Demarcation of the infarct area was performed in separate
groups of PBS- and liraglutide-treated mice using either 2,3,5-triphenyl tetra-
zolium chloride (TTC) or hematoxylin and eosin (H-E) staining at 2 and 28
days post-MI, respectively, as described (20,21). Sections from three levels of
each heart (5 m: apical, midventricular, and basal) were stained with H-E and
scanned, and the circumference of the ﬁbrotic infarct area and entire left
ventricle was measured with Image J software (NIH). The mean of measure-
ments of percent infarct size (circumference) was then calculated (infarct
circumference/total LV circumference  100%).
For analysis after TTC staining, hearts were sectioned perpendicular to the
long axis with a thickness of 	2 mm from the apical, midventricular, and basal
(immediately below the ligation point) regions and incubated in the pre-
warmed (30°C) fresh TTC solution for 15 min. They were then weighed and
transferred to a 4% paraformaldehyde solution for 1 h before image acquisition
with a digital camera. Infarct and total left ventricle areas were then measured
by Image J for determination of percent infarct size (area) by calculation
(infarct area/total LV area  100%).
Zymography. Matrix metalloproteinase-9 (MMP-9) was assessed in the infarct
zone 4 days post-MI as described (22).
Cell culture, cAMP assay, and tumor necrosis factor-–induced
apoptosis. Cardiomyocytes from newborn mice were prepared using a
modiﬁed protocol (23). For cAMP assay, neonatal mouse cardiac myocytes
were preincubated with IBMX (250 mol/l; Sigma) for 30 min to inhibit cAMP
degradation followed by subsequent treatment periods of 20 min for lira-
glutide (100 nmol/l), 30 min for the GLP-1R antagonist exendin (Ex)
9–39 (1
mol/l), and 15 min for forskolin (100 nmol/l). For the liraglutide  Ex
9–39
treatment, cells were exposed to Ex
9–39 for 30 min before coincubation with
fresh Ex
9–39 and liraglutide for an additional 20 min. All experiments were
performed in quadruplicate. Samples were collected and analyzed using a
cAMP radioimmunoassay kit (Amersham, Little Chalfont, U.K.). For tumor
necrosis factor-
 (TNF-
) experiments, cells were grown on six-well
dishes, serum deprived for 24 h, incubated for 1 h with 10,100 or 1,000
nmol/l doses of liraglutide with or without 10 mol/l Ex
9–39 followed by
coincubation with liraglutide and TNF-
 (100 ng/ml; Sigma) for another
24 h to induce apoptosis (24). As a positive control for the induction of
apoptosis, another group of cardiomyocytes was exposed to 0.5 mol/l
H2O2 as described (25). All experiments were performed in triplicate.
Western blot analysis using whole cell extracts was used to quantify levels
of cleaved caspase 3.
Western blot. Extracts from cells, whole hearts, and infarct regions were
prepared as described (26). Rabbit polyclonal primary antibodies against
GLP-1R (LS-A1205; MBL International), Nrf2 (C20; Santa Cruz Biotechnology),
heme-oxygenase-1 (HO-1; Stressgen), peroxisome proliferator–activated re-
ceptor (PPAR)-/ (H-74; Santa Cruz), and monoclonal antibodies against Akt,
phospho-Akt (Ser473), glycogen synthase kinase (GSK)-3, phospho-GSK-3
(Ser9), and cleaved-caspase 3 (all from Cell Signaling) as well as goat-
polyclonal anti–atrial natriuretic peptide (ANP) antibodies (Santa Cruz) were
used per manufacturers’ instructions. Mouse monoclonal anti–-actin (Sigma)
and anti–transcription factor II D (TFIID) (Santa Cruz) antibodies and a rabbit
polyclonal anti-GAPDH (Santa Cruz) were used to evaluate the amount of
protein loaded in each sample.
RT-PCR. Total RNA was isolated from hearts using TRIZOL (Invitrogen),
quantiﬁed (2 g), and treated with DNase-I. cDNA synthesis was performed by
Superscript III reverse transcriptase (Invitrogen) and speciﬁc primers for
HO-1 (F: GGC-CTT-CTG-GTA-TGG-GCC-TCA-CTG-G; R: GCC-TCT-GAC-GAA-
GTG-ACG-CCA-TCT-G) and Nrf2 (F: TCT-CCT-CGC-TGG-AAA-AAG-AA; R:
AAT-GTG-CTG-GCT-GTG-CTT-TA). PCR products were visualized on 1.5%
agarose gels with ethidium bromide. GAPDH reaction product served as a
loading and RT efﬁciency control.
Ischemia-reperfusion. Isolated hearts were prepared as previously de-
scribed (27). Isolated hearts underwent a 20-min equilibration phase followed
by a 40-min perfusion phase during which LV developed pressure (LVDP) was
continuously recorded. Then, 30 min of sustained global ischemia was
generated by clamping inﬂow to the heart followed by reperfusion for 40 min.
In some experiments, liraglutide was added to the buffer during the ﬁnal 20
min of the perfusion phase (i.e., preischemia); in others, it was added to the
buffer only during reperfusion (i.e., postischemia). Recovery of LVDP was
measured at the end of reperfusion. These experiments were also performed
using hearts isolated from mice after 1 day (acute) or 7 days (chronic) of
twice-daily liraglutide (200 g/kg i.p.).
Ultrasound biomicroscopy. Image acquisition and data analysis were car-
ried out as described (28,29). Three groups of nondiabetic mice, including 8
control mice not subjected to LAD occlusion, and 15 liraglutide-treated and 15
saline-treated mice were studied on day 28 post-MI using high-frequency
ultrasound imaging. Identical procedures were used to image diabetic mice
(sham, n  5/group; LAD-ligated, n  10–11/group).
All data are expressed as mean  SE. Survival analysis was done by the
Kaplan-Meier method (Fig. 1A and B). Student’s t test was used to compare
two groups for data shown in Figs. 2–4. For analysis of echocardiographic
data (Table 1) and speciﬁc time points in ischemia-reperfusion (I/R) experi-
ments (Fig. 5) and cAMP and TNF-
 studies (Fig. 6), a one-way ANOVA was
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the Student-Newman-Keuls (SNK) post hoc test was used for pairwise
multiple comparisons. Signiﬁcance was deﬁned as P  0.05.
RESULTS
Liraglutide increased survival in mice post-MI. Imme-
diate perioperative mortality (within 24 h of LAD ligation)
was 8.3% in PBS- (n  85) and 5% in LIR 200–treated (n 
60) mice (P  0.43) with no deaths in the sham-operated
animals (n  20). By day 28 post-MI, LIR 200–treated mice
exhibited reduced mortality compared with PBS-treated
controls (12 of 60 versus 46 of 60; P  0.0001) (Fig. 1A).
Because mice treated with LIR 200 also exhibited weight
loss compared with PBS-treated controls (1.65  0.05
versus 0.72  0.02 g; P  0.0001), we carried out
additional experiments to determine whether the effects of
LIR on survival post-MI were dependent on weight loss. A
separate group of mice was pair-fed to achieve weight loss
comparable to that of animals receiving LIR 200 for 7 days;
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FIG. 1. Liraglutide pretreatment improves outcomes after MI in mice. Kaplan-Meier survival curves show survival after MI in nondiabetic mice
(A): sham (n  20), liraglutide-MI (75 g/kg, n  35 or 200 g/kg, n  60), PBS-MI (n  60), and pair-fed mice (n  25), P  0.0001 for LIR 75
and 200 versus PBS; and diabetic mice (B): sham (n  15, 5/treatment group), PBS-MI (n  18), metformin-MI (n  18), liraglutide-MI (75 g/kg,
n  18), P  0.04 for LIR 75 versus PBS. C: Frequency and timing of cardiac rupture in nondiabetic mice is shown as a percentage of total group.
One-week pretreatment with liraglutide (200 or 75 g/kg i.p. twice daily) had no signiﬁcant effects on random blood glucose levels in adult
nondiabetic mice (PBS: 7.6  4.0 versus LIR 200: 6.3  0.6 versus LIR 75: 6.1  0.4 mmol/l; P  0.72). Blood glucose levels in diabetic mice are
shown in supplemental Table 1 (available in the online appendix).
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with LIR 200 versus pair-fed controls (Fig. 1A). We next
assessed a range of liraglutide doses on food intake and
body weight and then determined the effect of pretreat-
ment with a weight-neutral dose, LIR 75, on post-MI
survival. Mice treated with LIR 75 for 7 days did not
experience signiﬁcant weight loss (0.30  0.06 g; P  0.85)
but exhibited a marked improvement in survival after LAD
ligation (Fig. 1A, P  0.0001). Similarly, pretreatment of
diabetic mice for 1 week with LIR 75 also reduced mor-
tality after LAD occlusion (Fig. 1B, P  0.04); in contrast,
comparable treatment with metformin that produced
equivalent reduction in glycemia (supplemental Table 1,
available in the online appendix) did not improve survival
after MI (P  0.5, not signiﬁcant). Together, these data
suggest that pretreatment with liraglutide enhances sur-
vival after MI independent of effects on body weight or
blood glucose.
Liraglutide prevented cardiac rupture post-MI. To
understand the mechanisms by which LIR improves out-
comes after MI in mice, we performed postmortem exam-
inations of all animals. Excluding day 1, postmortem
analysis in nondiabetic mice revealed that all spontaneous
death events within 10 days post-MI were associated with
evidence of cardiac rupture. Timing and incidence of
cardiac rupture differed among the groups, occurring as
early as day 3 post-MI and peaking in incidence at day 5
post-MI in PBS-treated mice (Fig. 1C). By contrast, mice
pretreated with LIR 200, and to an even greater extent LIR
75, exhibited fewer and later cardiac rupture events
post-MI (Fig. 1C).
Liraglutide reduced infarct expansion post-MI. Car-
diac rupture is known to occur more frequently with larger
infarcts (30) and is believed to manifest an imbalance
between inﬂammatory and ﬁbrotic responses as well he-
modynamic forces acting on the infarct (31,32). To explore
these possibilities in more detail, we ﬁrst analyzed H-E–
deﬁned infarct size at day 28 post-MI in nondiabetic mice.
Liraglutide (LIR 200) signiﬁcantly reduced infarct size
compared with PBS-treated mice (20.9  1.7 versus 28.8 
3.3; percent total LV circumference, P  0.02) (Fig. 2).
Furthermore, cardiac hypertrophy, as manifested by heart
weight/body weight (HW/BW) ratio, was signiﬁcantly re-
duced in LIR 200–treated mice (Fig. 2). To determine if
these results partly reﬂected survivor bias, we also exam-
ined TTC-deﬁned infarct size at day 2 post-MI. This anal-
ysis revealed no signiﬁcant difference in infarct size
between LIR 200– (n  14) and PBS-treated (n  15)
groups (40.2  4.2 versus 39.3  3.8; P  0.86). Despite
signiﬁcantly higher survival in liraglutide-treated diabetic
mice (Fig. 1B), no differences were observed in either
infarct size or HW/BW ratios in diabetic animals at day 28
post-MI (data not shown).
Liraglutide activates cardioprotective signaling path-
ways in the heart. To determine the mechanisms under-
lying liraglutide-induced improvements in survival and
infarct remodeling post-MI, we studied the expression of
selected genes and proteins known to modulate cardiomy-
ocyte survival. LIR 200 administered twice daily for 7 days
to normal healthy mice (without MI) increased phosphor-
ylation of the prosurvival kinase Akt (pAkt/Akt: 2.10 
0.01-fold over control, P  0.002, Fig. 3A). Similarly,
liraglutide increased phosphorylation and thereby reduced
the activity of GSK3, a known Akt substrate, and in-
creased levels of the nuclear receptor PPAR/ and the
redox-sensitive basic leucine zipper transcription factor
Nrf2. Liraglutide also induced mRNA and protein levels of
HO-1 (Fig. 3A), a protein strongly implicated in cardiopro-
tection in response to ischemic injury (33). To assess the
importance of the known GLP-1R for the actions of
liraglutide, we administered LIR 75 for an identical 7-day
treatment period in mice with genetic absence of a func-
tional GLP-1R and littermate controls. Liraglutide in-
creased phosphorylation of Akt and GSK3 in both wild-
type (Fig. 3B) and Glp1r/ littermate controls (Fig. 3C),
but not in Glp1r-/- mice (Fig. 3D).
To assess whether the effects of liraglutide remained
detectable after cessation of liraglutide therapy and before
the peak incidence of mortality post-MI (which occurred
on day 5; Fig. 1A), we examined the hearts of liraglutide-
and PBS-treated controls 4 days post-MI (i.e., 4 days after
the ﬁnal dose of liraglutide or PBS). The HW/BW ratio was
reduced in liraglutide-treated mice (5.53  0.14 versus
5.83  0.15 mg/g; P  0.03) at day 4, and levels of
phosphorylated Akt were signiﬁcantly higher in the infarct
area of hearts from liraglutide-treated mice (Fig. 4). Simi-
larly, liraglutide pretreatment was associated with in-
creased GSK phosphorylation at Ser 9 and a signiﬁcant
reduction in levels of cleaved caspase-3 and ANP (Fig. 4).
Quantitative gelatin zymography showed a signiﬁcant de-
crease in MMP-9 activity in hearts from liraglutide-treated
mice (Fig. 4). These data demonstrate a persistent effect of
liraglutide pretreatment on cardiac prosurvival and remod-
eling pathways detectable both before (Fig. 3) and after
(Fig. 4) induction of ischemic injury.
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FIG. 2. Effects of liraglutide pretreatment on infarct size and heart
weight. A: Representative photomicrographs of H-E–stained hearts 28
days post-MI depict decreased infarct size (arrows) in liraglutide- (n 
36) versus PBS-treated mice (n  21) as conﬁrmed by morphometric
quantiﬁcation of percent total LV circumference (*P  0.025). B:
HW/BW ratio was reduced in liraglutide- versus PBS-treated mice 28
days post-MI (n  36 and 21, respectively; **P  0.001). Data shown
are means  SE. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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performance. The results of cardiac ultrasound biomi-
croscopy performed 4 weeks after LAD ligation or sham
surgery in nondiabetic mice are shown in Table 1. After
experimental MI, measures of systolic function such as
cardiac output and stroke volume were signiﬁcantly in-
creased in liraglutide-treated mice. Measures of diastolic
function such as mitral inﬂow velocities (E/A ratio) were
also improved in liraglutide-treated mice and LV dilatation
in the liraglutide-treated group was less severe than in
PBS-treated control mice (Table 1). In contrast, although
liraglutide-treated diabetic mice exhibited a signiﬁcant
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FIG. 3. Effects of liraglutide pretreatment on levels of cardiac genes and proteins. The expression of genes/proteins before left anterior
descending ligation is analyzed in liraglutide-treated hearts. A: Representative Western blots for wild-type mice treated with LIR 200 as outlined
in supplemental Fig. 1 (available in the online appendix). Corresponding densitometric quantiﬁcation (n  6/group) of fold changes in
phosphorylation of prosurvival kinases Akt and GSK3 and in expression of PPAR-/, Nrf2, and HO-1 are shown in the top ﬁve panels. The
bottom panel depicts a representative agarose gel (n  6/group) showing HO-1–speciﬁc mRNA levels by RT-PCR. Data shown are means  SE;
*P < 0.05. B–D: Representative Western blot analysis of cardiac prosurvival kinases in LIR 75–treated wild-type (B), LIR 75–treated Glp1r/
littermate controls (C), and LIR 75–treated Glp1r-/- (D) mice, respectively.
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MI, no consistent differences in echocardiographic param-
eters were detected in diabetic mice treated with lira-
glutide versus metformin at day 28 post-MI (data not
shown).
Liraglutide treatment in vivo prevented ischemia–
reperfusion injury of isolated hearts ex vivo. To
determine whether liraglutide exhibits rapid cardioprotec-
tive actions in the isolated mouse heart ex vivo, we
examined the effects of acute liraglutide administration in
the isolated perfused mouse heart. Direct infusions of
liraglutide immediately before and postischemia did not
improve functional recovery after ischemia-reperfusion
(I/R) injury in the isolated mouse heart (Fig. 5A). In
contrast, pretreatment of normal healthy mice with lira-
glutide (200 g/kg b.i.d.) in vivo for 1 or 7 days before
heart isolation enhanced recovery of LVDP after I/R rela-
tive to untreated controls (1 day: 41.54  1.5, n  4; 7 days:
38.31  0.6 mmHg, n  5; untreated: 28.24  1.8 mmHg,
n  5; P  0.01, Fig. 5B). These results imply that
liraglutide-induced cardioprotection may require a mini-
mum dose or pretreatment period for the activation of a
cardiac gene and protein expression proﬁle and/or may be
indirect, reﬂecting the consequences of GLP-1R activation
in noncardiac tissues.
Liraglutide induces cAMP and reduces apoptosis in
neonatal mouse cardiomyocytes. We next examined
whether liraglutide exerts direct actions on mouse cardi-
omyocytes. Liraglutide (100 nmol/l) signiﬁcantly increased
cAMP formation in mouse cardiomyocytes (P  0.0001) in
a GLP-1R–dependent manner, because cAMP stimulation
was abolished by the GLP-1R antagonist Ex
9–39 (Fig. 6A).
To determine whether liraglutide directly modulates car-
diomyocyte survival, we examined the effects of liraglutide
in TNF-
–treated neonatal cardiomyocytes. Liraglutide
dose-dependently reduced TNF-
–induced activation of
caspase 3 in cardiomyocytes in vitro. Furthermore, the
protective effect of liraglutide was completely abolished
after coincubation of cells with Ex
9–39 (Fig. 6B).
DISCUSSION
In the present study, we demonstrate that liraglutide
administration induced changes in the expression of car-
dioprotective proteins in the normal nonatherosclerotic
murine heart characterized by phosphorylation of Akt and
GSK3 and increased expression of Nrf2, PPAR-/, and
HO-1. These changes were associated with improved sur-
vival of mice after experimental ischemia despite cessa-
tion of liraglutide therapy. These ﬁndings, taken together
with the results of echocardiography, demonstrate that a
brief 7-day period of liraglutide pretreatment leads to
improvements in cardiomyocyte survival and sustained
improvement in cardiac function that remain detectable
even 4 weeks after cessation of liraglutide and induction of
experimental MI.
P-Akt
Akt
MMP-9
P-GSK-3β β
GSK-3β
ANP
GAPDH
Act. Caspase 3
GAPDH
CB band
PBS Liraglutide
*
*
*
*
*
0
1
2
3
0
1
2
3
4
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
PBS Liraglutide
0.0
0.2
0.4
0.6
0.8
1.0
FIG. 4. Effects of liraglutide pretreatment on cardioprotective signaling
pathways after MI in mice. Liraglutide pretreatment for 7 days has
persistent cardioprotective effects detectable 4 days post-MI as indicated
by representative Western blots and corresponding densitometric quan-
tiﬁcation (n  6/group) of fold changes in phosphorylation of Akt and
GSK3, cleavage of caspase-3, and expression of ANP and activity of
MMP-9 by zymography in liraglutide- versus PBS-treated mice. Data
shown are means  SE; *P < 0.05.
TABLE 1
Ultrasound biomicroscopy-deﬁned cardiac dimensional, func-
tional, and hemodynamic parameters in mice on day 28 postop-
eratively
Parameter Sham MI-placebo MI-liraglutide
n 81 5 1 5
Body weight (g) 27.9  0.3 29.5  0.4 29.3  0.5
Aortic ﬂow
Heart rate (bpm) 393  12 451  18 435  12
Peak velocity
(cm/s) 86.3  2.2 68.7  2.7* 80.3  3.2†
VTI (cm) 3.03  0.08 2.09  0.13* 2.61  0.12*†
AO diameter (mm) 1.15  0.02 1.15  0.02 1.19  0.01
LV SV (l) 31.3  0.9 22.1  1.8* 28.8  1.4†
CO (ml/min) 12.3  0.5 9.7  0.6* 12.4  0.6†
Mitral ﬂow
Heart rate (bpm) 413  11 433  14 424  9
Peak E velocity
(cm/s) 71.8  1.9 59.0  3.6* 59.9  2.2*
Peak A velocity
(cm/s) 47.0  1.5 30.8  3.5* 43.6  2.0†
Peak E/A ratio 1.54  0.04 2.54  0.44* 1.40  0.06†
LV chamber
dimensions by
M mode
Heart rate (bpm) 417  10 442  17 441  15
LV EDD (mm) 4.33  0.05 6.12  0.23* 5.52  0.09*†
LV ESD (mm) 3.33  0.08 5.73  0.30* 5.02  0.14*†
LV FS (%) 23.0  1.2 7.0  1.5* 9.2  1.3*
Data are means  SE. In mitral inﬂow, the peak E velocity represents
the maximal velocity of the early diastolic wave caused by active LV
relaxation. The peak A velocity represents the maximal velocity
caused by left atrial contraction in late diastole. *Difference (P 
0.05) with the corresponding value in the sham controls. †Difference
(P  0.05) with the corresponding value in the placebo (PBS)-treated
controls. AO, aortic oriﬁce; CO, cardiac output; FS, fractional
shortening; SV, stroke volume; EDD, end-diastolic diameter; ESD,
end-systolic diameter; VTI, velocity–time integral of Doppler ﬂow
waveform.
LIRAGLUTIDE ACTIVATES CYTOPROTECTIVE PATHWAYS
980 DIABETES, VOL. 58, APRIL 2009The beneﬁcial effects of liraglutide were independent of
weight loss, because a lower dose of liraglutide (75 g/kg)
that did not produce weight loss also protected the heart
and increased survival to a greater extent than that ob-
served with the higher 200 g/kg liraglutide dose. The
weight loss observed with higher pharmacological doses
of GLP-1R agonists is not required for the beneﬁcial effects
of these agents on cardiovascular function (2).
Although the mechanisms underlying the reduced car-
diac rupture and improved survival remain incompletely
understood, notable ﬁndings from our studies include the
modulation of putative mediators (Akt, GSK3, HO-1,
PPAR-/,andNrf2)knowntobeimportantforcardiomyo-
cyte survival (34–38). We observed reduced levels of
MMP-9 and cleaved caspase 3 in the infarct region of
liraglutide-treated mice at day 4 post-MI. These ﬁndings
are reminiscent of observations made in studies of the
effects of GLP-1 on survival of -cells and neurons, in
which GLP-1R activation leads to inhibition of caspase
activation and increased cytoprotection (39,40).
Functional assessment with echocardiography showed
that LV systolic function remained improved even 4 weeks
after the last dose of liraglutide. We observed signiﬁcantly
less dilatation of the left ventricle of liraglutide-treated
mice. These ﬁndings are consistent with preclinical data
demonstrating that GLP-1R agonists improve LV function
in rodent and canine models of experimental cardiac
dysfunction (8,9,11–13,41). The sustained beneﬁts of tran-
sient liraglutide therapy that persisted for weeks after
cessation of therapy is consistent with studies demonstrat-
ing that a 72-h infusion of GLP-1 in human subjects after
MI produces sustained improvements in cardiovascular
function that remained detectable even months after ces-
sation of GLP-1 administration (14).
An unexpected ﬁnding was the observation that lira-
glutide, unlike native GLP-1 or GLP-1
9–36 (3), was not
effective in directly improving LV pressure, or recovery of
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FIG. 6. Liraglutide induces cAMP formation and reduces caspase-3
activation in murine cardiomyocytes in vitro. A: Liraglutide (100
nmol/l) increases cAMP formation in cultured neonatal cardiomyo-
cytes. The actions of liraglutide were abolished by the GLP-1R antag-
onist exendin
9–39. ***P < 0.001. B: Liraglutide (L: 10–1,000 nmol/l)
reduced TNF-–induced activation of caspase-3 in a dose-dependent
manner in cultured neonatal mouse cardiomyocytes. Cotreatment with
exendin
9–39 (Ex: 10 mol/l) abolished the protective effects of lira-
glutide. Positive control represents treatment of cells with the potent
apoptosis-inducing agent H2O2. Data shown are means  SE; *P < 0.01
and **P < 0.001 versus cultures only treated with TNF.
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immediately before induction of ischemia or during the
reperfusion phase to isolated hearts ex vivo. In contrast,
administration of liraglutide in vivo for as little as 1 day
(two injections) before ischemia was sufﬁcient to confer a
cardioprotective beneﬁt in subsequent I/R experiments.
Our ﬁndings raise the possibility that the cardioprotective
actions of liraglutide are complex and may require a
speciﬁc minimum dose or deﬁned time period for induc-
tion of a protective gene/protein proﬁle that promotes
resistance to cardiomyocyte injury. Alternatively, the car-
dioprotective actions of liraglutide observed in vivo may
be partly indirect, mediated perhaps through neural, hor-
monal, or metabolic factors. This latter possibility con-
trasts with ﬁndings demonstrating direct protection by
native GLP-1 in I/R studies (9,10,42).
Recent studies have implicated a role for the metabolite
GLP-1
9–36 as a cardioactive peptide with inotropic effects
in dogs with heart failure (41). The GLP-1 metabolite,
GLP-1
9–36, also exerts cardioprotective actions when ad-
ministered postischemia (3,16), further highlighting the
complexity of different GLP-1–related peptides on the
ischemic heart. Liraglutide is relatively resistant to cleav-
age by DPP-4 and contains two amino acid modiﬁcations,
a substitution and an addition, together with a fatty acid
side chain. Whether liraglutide is metabolized to a peptide
with GLP-1
9–36–like activity remains unclear. The observa-
tion that liraglutide fails to induce the phosphorylation of
Akt and GSK3 in the Glp1r-/- heart, together with the
demonstration that liraglutide increased cAMP and re-
duced apoptosis in cardiomyocyte cultures in a GLP-1R–
dependent manner, strongly implicates the known GLP-1R
as a critical mediator of liraglutide action in the murine
heart.
Drugs acting on the GLP-1R axis have been approved for
the treatment of diabetes and have the added beneﬁts of
reducing appetite and body weight and, in some instances,
blood pressure, leading to improvement of cardiovascular
risk factors (43,44). Given the experimental data presented
here and elsewhere (8,9,13,16), the possibility that these
agents may have beneﬁcial effects on cardiovascular out-
comes of patients with diabetes, independent of improve-
ments in blood pressure and blood glucose, requires
further study.
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